A Phase I, Dose Escalation Study to Evaluate the Tolerability and Antitumor Activity of Icotinib in Patients with Advanced Non Small Cell Lung Cancer (NSCLC)
Latest Information Update: 04 Dec 2015
Price :
$35 *
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2015 New trial record